Filament Health signs supply and licensing deal for PEX010 psilocybin study
Rhelion Life Sciences says its wholly owned subsidiary Filament Health signed a supply and licensing agreement with the Centre for Human Drug Research for PEX010 in a study of low and medium dose psilocybin.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.